ScreenerHero

EWTXEdgewise Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · edgewisetx.com
44.18USD-4.87%Mkt Cap: 4.80B $P/E: —

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small mole…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap4.80B $
Enterprise Value4.24B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-167.79M $
Revenue/Share—
Last Price44.18 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees127
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-23.84
PEG—
EV/EBITDA-19.58
EV/Revenue—
P/S—
P/B10.41
EPS (TTM)-1.72
EPS (Forward)-1.82
52W Range
13.5388% of range48.40
52W High48.40 USD
52W Low13.53 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-32.13%
ROA-30.36%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-143.82M $
CapEx (TTM)256.00K $
FCF Margin—
FCF Yield-1.92%
Net Debt-457.12M $
Net Debt/EBITDA2.11
Balance Sheet
Debt/Equity0.01
Current Ratio16.24
Quick Ratio15.86
Book Value/Sh4.157 USD
Cash/Share4.242 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)51.69 USD
Upside (mean)+17.0%
Target Range36.00 USD – 66.00 USD
$36.00+17.0% to mean$66.00
# Analysts13
Ownership
Shares Out.108.60M
Float74.29M
Insiders0.49%
Institutions111.83%
Short Interest
Short Ratio9.7d
Short % Float12.76%
Short % Out.9.06%
Shares Short9.84M
Short (prev mo.)10.49M
Technical
SMA 5040.77 (+8.4%)
SMA 20031.67 (+39.5%)
Beta0.33
S&P 52W Chg18.16%
Avg Vol (30d)1.10M
Avg Vol (10d)1.31M
Technical Indicators
RSI (14)55.2
MACD1.3273
MACD Signal1.2184
MACD Hist.+0.1088
BB Upper47.40 USD
BB Middle42.59 USD
BB Lower37.78 USD
BB Width22.58%
ATR (14)2.401 USD
Vol Ratio (20d)0.97x